Search This Blog

Friday, February 14, 2025

Retired Russian Colonel Claims Trump "Has Dirt" On Zelensky That Will Force Him To Compromise

 by Liz Heflin via Remix News,

Retired Russian Armed Forces Intelligence Colonel Anatoly Matviychuk has come out swinging in the lead-up to the Munich Security Conference, saying the U.S. has compromising information on Zelensky that will force him to compromise, namely, that he has possibly embezzled large amounts of money from the funds sent to Ukraine for its defense against Russia. 

In an interview with MK, the retired colonel said that President Trump “has long had a grudge against Zelensky,” since the head of the Kyiv regime supported his persecution and passed on compromising information about him to the previous U.S. administration under Biden.

“Today, Trump is skillfully dealing with everyone who once spoke out against him,” Matviychuk noted.

“Among them are Zelensky and Yermak. I am sure that Trump has more than enough dirt on them.”

These may have to do with the embezzlement of money. 

“It is not surprising that it has now become clear that about 100 billion dollars have sunk into oblivion,” the intelligence officer noted.

“I believe that in fact the U.S. knows very well where these billions ended up…”

Matviychuk claims the money ended up in Zelensky’s Spanish, Italian and British real estate. However, he also went after Zelensky’s wife. 

“In addition, the million-dollar expenses of the First Lady of Ukraine, Elena Zelenskaya, in European boutiques have been well calculated,” the expert added.

Matviychuk added that Zelensky has also opened himself up to accusations of prolonging the conflict and numerous war crimes.

This is not the first time someone has claimed Zelensky has enriched himself from U.S. taxpayer money sent for his country’s defense against Russia. 

The Organized Crime and Corruption Reporting Project found that Zelenskyy and his partners owned a network of offshore companies dating back to 2012 in the British Virgin Islands, Cyprus and Belize.

The documents also revealed that before Zelenskyy became president in 2019, he gave his stake in an offshore company to a business partner but made an arrangement that the offshore company would continue paying dividends to a company Zelenskyy’s wife owned, the reporting project said.

In response, USA Today offered up its own “fact check,” stating:

“The Pandora Papers – secret records obtained by the International Consortium of Investigative Journalists – highlight information about Zelenskyy’s overseas dealings. However, the papers don’t reveal the exact amount Zelenskyy or his wife have in overseas accounts. Sullivan said none of the assets claimed in the social media post were in the papers.”

USA Today also cites a 2022 Forbes piece that estimated Zelensky’s real estate portfolio at some $4 million after reports that he purchased his parents an $8 million mansion — although USA Today said the claims about an $8 million mansion were false. Nor did the magazine find any proof to back up claims that Zelensky owned three private jets or five luxury yachts. The original Instagram post targeted by USA Today reportedly stating that Zelenky owned “a 35 million dollar home in Florida and has $1.2 billion in an overseas bank account” is no longer available. 

Despite no hard evidence of embezzlement, allegations have continued non-stop, with many saying that now that Donald Trump is in office, a real audit will uncover the truth. 

Tucker Carlson headlined a recent episode of his podcast by claiming “Ukrainian military is selling American weapons systems on the black market, including to drug cartels on the (American) border.” 

His guest U.S. Col. Daniel Davis said that Zelensky had even recently made a point of denying such allegations, and “the media just reports what he says.” The colonel then added that this has been “an open secret for almost the duration of (the war).”

https://www.zerohedge.com/geopolitical/retired-russian-colonel-claims-trump-has-dirt-zelensky-will-force-him-compromise

House GOP Strikes Deal To Cut $1.5 T From Budget, Paving Way for Trump's Legislative Agenda

 Days after Democrats threatened to shut down the government in response to Elon Musk and DOGE shutting down the government - planning to deprive House Speaker Mike Johnson of a few Democrat votes to override GOP hardliner holdouts to avoid an upcoming government shutdown, the joke's on them. 

On Thursday, hard-line conservatives and House Republican leadership reached a last-minute agreement on the party’s budget resolution, smoothing the path for the measure to advance out of committee and setting the stage for a broader push on former President Donald J. Trump’s legislative priorities.

The deal, brokered shortly before a key committee vote, allows Representative Jodey Arrington (R-TX) and the chairman of the Budget Committee, to adjust spending caps and tax provisions within the framework. If approved, the resolution would unlock the budget reconciliation process, which Republicans aim to use to push Trump’s policies forward without Democratic support.

"This is it. We declare victory," Representative Andy Harris (R-MD) and chair of the House Freedom Caucus, said following the agreement. "We have a bill that delivers meaningful deficit reduction, funds the border, and advances the president’s tax policy. It all happens here."

A Balancing Act on Spending and Taxes

The budget resolution, released by Arrington on Wednesday, outlines at least $1.5 trillion in spending cuts across government programs, with a target of $2 trillion in deficit reduction. It also sets a $4.5 trillion cap on the deficit impact of extending Trump’s 2017 tax cuts while allocating $300 billion in additional funding for border security and defense.

Negotiations in recent weeks had focused on bridging differences between fiscal conservatives demanding deeper spending reductions and members of the tax-writing Ways and Means Committee, who sought a higher cap to accommodate Trump’s tax agenda. The agreement allows Arrington to adjust the spending floor and tax cap based on final deficit reduction figures, potentially increasing the tax cut allowance to $5 trillion if additional savings are found elsewhere.

"This budget put forward by the chairman is a giant step forward to reduce spending, the primary driver of the inflation, and the expansion of the government largesse that is strangling the future of our children and grandchildren” said Rep. Chip Roy (R-TX), signaling his support for the measure after expressing skepticism earlier in the week, adding "I am proud of what the chairman has put forward."

Hard-Liners Move Toward Support

The deal appears to have won over key conservative holdouts on the House Budget Committee. Rep. Ralph Norman (R-SC), a member of the Freedom Caucus, had voiced opposition to the resolution on Wednesday, citing concerns over Medicaid work requirements and block grants. By Thursday, he expressed optimism about its chances of passing out of committee.

Republicans can afford to lose only two votes on the committee to advance the resolution, assuming all Democrats oppose it. The manager’s amendment could also secure support from Rep. Jason Smith (R-MO) and chair of the Ways and Means Committee, who had pushed for a higher tax cap.

“Let me just say that a 10-year extension of President Trump’s expiring provisions is over $4.7 trillion, according to [the Congressional Budget Office],” Smith said earlier this week. “Anything less would be saying that President Trump is wrong on tax policy.”

https://www.zerohedge.com/political/house-republicans-strike-deal-cut-15-trillion-budget-paving-way-trumps-legislative-agenda

Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights

 

  • Combined Net Product Revenue: $1.646 billion for 2024, representing 33% growth compared to 2023.

  • TTR Franchise Revenue: $343 million in Q4 2024, a 35% increase compared to Q4 2023.

  • Full Year TTR Revenue: $705 million in the US, a 39% increase compared to 2023.

  • Rare Franchise Revenue: $108 million in Q4 2024, an 18% increase compared to Q4 2023.

  • Gross Margin on Product Sales: 81% for the full year 2024, a 3% increase compared to 2023.

  • Non-GAAP Operating Income: $95 million for the full year 2024.

  • Cash, Cash Equivalents, and Marketable Securities: $2.7 billion at the end of 2024.

  • 2025 Revenue Guidance: $2.05 billion to $2.25 billion in combined net product sales.

  • 2025 TTR Revenue Guidance: $1.6 billion to $1.725 billion, assuming approval and launch of AMVUTTRA for ATTR cardiomyopathy.

  • 2025 Rare Revenue Guidance: $450 million to $525 million.

  • 2025 Collaboration and Royalty Revenue Guidance: $650 million to $750 million.

  • 2025 Non-GAAP R&D and SG&A Expenses: $2.1 billion to $2.2 billion.



  • Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) reported strong financial performance with combined net product revenues of over $1.6 billion, achieving a 33% growth compared to 2023.

  • The company achieved a significant milestone with $95 million in non-GAAP operating income for the full year, marking its first year of profitability.

  • The HELIOS-B Phase III study yielded highly positive results, leading to the submission of global regulatory filings for vutrisiran in ATTR cardiomyopathy.

  • Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a robust pipeline with numerous multibillion-dollar opportunities, including the advancement of Nucresiran, which received orphan drug designation for ATTR amyloidosis.

  • The company maintained its award-winning culture, which has been a critical enabler of its success, and is poised for sustainable growth and value creation in 2025 and beyond.

Negative Points

  • The launch of AMVUTTRA for ATTR cardiomyopathy is expected to face delays in formulary uptake, with meaningful demand anticipated only in the second half of 2025.

  • Gross margin on product sales is expected to decrease in 2025 due to the increased royalty burden on AMVUTTRA sales.

  • The company faces competition in the market, particularly in the polyneuropathy segment, which could impact its market share and growth.

  • There is uncertainty regarding payer policies and the establishment of value-based agreements for the expanded label of AMVUTTRA in cardiomyopathy.

    • Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) anticipates increased R&D and SG&A expenses in 2025, driven by clinical investments and the launch of AMVUTTRA, which could impact profitability.

    Q & A Highlights

    Q: How long will it take to establish payer policies after the approval of AMVUTTRA, and how might this impact the launch trajectory? A: Yvonne Greenstreet, CEO, mentioned that they are in a strong position due to their existing TTR franchise. Tolga Tanguler, Chief Commercial Officer, added that the formulary uptake is expected to be a second-half story, with meaningful uptake anticipated in the latter part of the year.

    Q: What are your thoughts on premium pricing for AMVUTTRA compared to other silencing therapies, and how might this affect commercial insured patients? A: Tolga Tanguler stated that they are encouraged by payer engagements and the value AMVUTTRA brings. They expect uptake to be consistent with past experiences in the polyneuropathy market, with a focus on maintaining growth.

    Q: Can you share the key factors impacting pricing adjustments for AMVUTTRA and the percentage of current sites with coding in place for its use? A: Yvonne Greenstreet emphasized the importance of considering product value and patient access when determining pricing. Tolga Tanguler noted that they already have a J code for AMVUTTRA, ensuring smooth coverage and access.

    Q: What is the progress on label discussions for AMVUTTRA, and will it include unique wording related to quality of life and functional capacity? A: Pushkal Garg, Chief Medical Officer, expressed enthusiasm about the FDA review process and expects the label to reflect the study's demonstrated benefits, including mortality and hospitalization reductions, as well as quality of life improvements.

    Q: How do you expect payer dynamics to evolve with the introduction of AMVUTTRA in the cardiomyopathy market? A: Tolga Tanguler explained that they anticipate similar dynamics to those seen in the polyneuropathy market, with favorable patient affordability and smooth access due to existing payer relationships and value-based agreements.

    For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides

 Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.

The COVID-19 vaccine maker reported quarterly sales of $966 million, down from $2.81 billion a year ago, beating the consensus of $942.8 million.

Net product sales for the fourth quarter of 2024 were $938 million, reflecting a 66% year-over-year decrease. This was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States, which shifted sales into the third quarter.

Additionally, international sales were lower than in 2023, reflecting the continued phase-out of advance purchase agreements.

The company reported $923 million in Spikevax (COVID-19 vaccine) sales in the fourth quarter of 2024, which includes $244 million in U.S. sales and $679 million in international sales. Spikevax sales for the full year 2024 were $3.1 billion.

In January, Moderna was awarded a tender to supply the European Union with its mRNA COVID-19 vaccine. Under the agreement, Moderna can provide the vaccine in several formats for up to four years.

For the fourth quarter, Moderna reported $15 million in mRESVIA (Respiratory syncytial virus (RSV) vaccine) sales. mRESVIA sales for the full year 2024 were $25 million.

The cost of sales for the fourth quarter of 2024 was $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million, including a non-cash charge of $238 million related to the termination of a contract manufacturing agreement.

Guidance: Moderna has reiterated its 2025 revenue outlook of $1.5 billion to $2.5 billion versus a consensus of $2.43 billion. Moderna expects revenue of approximately $0.2 billion in the first half of the year, reflecting the seasonality of its respiratory business.

“In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth,” said Stéphane Bancel, Chief Executive Officer of Moderna.

The company expects the cost of sales to be approximately $1.2 billion, with R&D expenses anticipated to be approximately $4.1 billion.

Capital expenditures for 2025 are expected to be approximately $0.4 billion, and year-end cash and investments for 2025 are projected to be approximately $6 billion.


https://finance.yahoo.com/news/moderna-struggles-declining-q4-covid-130406463.html

DaVita stake cut at Berkshire

 Warren Buffett's Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita, reducing its holdings in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.

In a regulatory filing, Berkshire said the February 11 sale was required pursuant to a share repurchase agreement, under which DaVita agreed on a quarterly basis to buy back enough shares to reduce Berkshire's ownership stake to 45%.

The April 2024 agreement also requires Berkshire to vote shares in excess of a 40% stake in accordance with the recommendation of DaVita's board of directors, Berkshire said.

Berkshire has owned DaVita shares since the fourth quarter of 2011.

The investment has been spearheaded by Ted Weschler, who joined Berkshire as a portfolio manager in 2012. He previously invested in DaVita at his former hedge fund firm, Peninsula Capital Advisors.

Weschler and Todd Combs, who joined Berkshire in 2010, help Buffett manage Berkshire's investment portfolio. Berkshire has not disclosed in recent months how much they oversee.

Buffett has led the Omaha, Nebraska-based conglomerate since 1965.


https://finance.yahoo.com/news/berkshire-sells-davita-shares-cuts-011248247.html